

Amendments to the Claims

The following listing of claims replaces all prior listings and versions of claims in this application.

1. (Currently amended) A synthetic ~~haptotactic polypeptide comprising peptide~~ derived from the carboxyl terminal sequence of human fibrinogen β chain, having an amino acid sequence as set forth in SEQ ID NO:1, or a functional analogue thereof comprising an amino acid sequence as set forth in SEQ ID NO:1 that has at least one amino acid substituted by a natural or synthetic non-naturally occurring amino acid wherein the polypeptide or analogue thereof peptide has a haptotactic activity, ~~wherein the polypeptide is other than an entire fibrinogen β chain.~~

Claims 2 to 9. (Cancelled)

10. (Currently amended) A composition comprising a ~~haptotactic polypeptide~~ comprising synthetic peptide derived from the carboxyl terminal sequence of human fibrinogen β chain, having an amino acid sequence as set forth in SEQ ID NO:1, or a functional analogue thereof comprising an amino acid sequence as set forth in SEQ ID NO:1 that has at least one amino acid substituted by a natural or synthetic non-naturally occurring amino acid wherein the polypeptide or analogue thereof peptide has a haptotactic activity, ~~wherein the polypeptide is other than an entire fibrinogen β chain.~~

11. (Original) The composition of claim 10, further comprising a pharmaceutically acceptable carrier.

12. (Original) The composition of claim 10, further comprising a biological agent.

Claims 13 – 21. (Cancelled)